Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation

We compared outcomes after treatment with direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and a recent cerebral ischemia.

[1]  Georgi Krastev,et al.  Dabigatran initiation in patients with non-valvular AF and first acute ischaemic stroke: a retrospective observational study from the SITS registry , 2020, BMJ Open.

[2]  S. Knecht,et al.  Der zweite Blick: praktische diagnostische und therapeutische Checks in der rehabilitativen Neurologie , 2020, Der Nervenarzt.

[3]  S. Warach,et al.  Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation , 2019, The Lancet Neurology.

[4]  G. D. De Marchis,et al.  Management of patients with stroke treated with direct oral anticoagulants , 2018, Journal of Neurology.

[5]  K. Kario,et al.  Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation　- SAMURAI-NVAF Study. , 2018, Circulation journal : official journal of the Japanese Circulation Society.

[6]  M. Power,et al.  Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study , 2018, The Lancet Neurology.

[7]  A. Luft,et al.  Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage , 2018, Annals of neurology.

[8]  K. Furie,et al.  Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non–Vitamin‐K Oral Anticoagulants (RAF‐NOACs) Study , 2017, Journal of the American Heart Association.

[9]  G. D. De Marchis,et al.  Early start of DOAC after ischemic stroke , 2016, Neurology.

[10]  S. Schwab,et al.  Early Initiation of Anticoagulation with Direct Oral Anticoagulants in Patients after Transient Ischemic Attack or Ischemic Stroke. , 2016, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[11]  E. Antman,et al.  Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) , 2016, Stroke.

[12]  P. Bovi,et al.  Early introduction of direct oral anticoagulants in cardioembolic stroke patients with non-valvular atrial fibrillation , 2016, Journal of Thrombosis and Thrombolysis.

[13]  E. Vicaut,et al.  One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. , 2016, The New England journal of medicine.

[14]  K. Kario,et al.  Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study , 2016, International journal of stroke : official journal of the International Stroke Society.

[15]  K. Lees,et al.  IV thrombolysis in very severe and severe ischemic stroke , 2015, Neurology.

[16]  D. Werring,et al.  The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods , 2015, International journal of stroke : official journal of the International Stroke Society.

[17]  W. Ageno,et al.  Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing The RAF Study , 2015, Stroke.

[18]  A. Luft,et al.  Recanalization Therapies in Acute Ischemic Stroke Patients: Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Outcome , 2015, Circulation.

[19]  K. Kario,et al.  Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: The SAMURAI‐NVAF Study , 2015, International journal of stroke : official journal of the International Stroke Society.

[20]  C. Chung,et al.  Eligibility and Preference of New Oral Anticoagulants in Patients With Atrial Fibrillation: Comparison Between Patients With Versus Without Stroke , 2014, Stroke.

[21]  Erika G Cordova,et al.  Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. , 2014, The Cochrane database of systematic reviews.

[22]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[23]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[24]  D. Leys,et al.  IV thrombolysis and renal function , 2013, Neurology.

[25]  M. Hori,et al.  Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. , 2012, Circulation journal : official journal of the Japanese Circulation Society.

[26]  B. Lewis,et al.  Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial , 2012, The Lancet Neurology.

[27]  G. Breithardt,et al.  Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF , 2012, The Lancet Neurology.

[28]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[29]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[30]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[31]  S. Yusuf,et al.  Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial , 2010, The Lancet Neurology.

[32]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[33]  Gerhard Schroth,et al.  What Is a Minor Stroke? , 2010, Stroke.

[34]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[35]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[36]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[37]  C. Molina,et al.  Patterns and Predictors of Early Risk of Recurrence After Transient Ischemic Attack With Respect to Etiologic Subtypes , 2007, Stroke.

[38]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[39]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[40]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[41]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[42]  T. Brott,et al.  Improved Reliability of the NIH Stroke Scale Using Video Training , 1994, Stroke.

[43]  R. Hart,et al.  Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. , 1983, Stroke.

[44]  E. Berge,et al.  Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. , 2018, The Cochrane database of systematic reviews.

[45]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[46]  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. , 1997, Lancet.

[47]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .